158 research outputs found
Treatment of vasculitis
LijeÄenje vakulitisa ovisi o etiologiji i tipu vaskulitisa. U lijeÄenju sistemskih vaskulitisa glukokortikodi su prvi lijekovi izbora. Dok je u vaskulitisima velikih krvnih žila Äesto dovoljna primjena samo glukokortikoida u s ANCA povezanim vaskulitisima gotovo uvijek je potrebna inicijalna kombinacija glukokortikoida i imunosupresiva (u težim oblicima ciklofosfamid, a u lakÅ”im metotreksat ili azatioprin). Terapija održavanja u s ANCA povezanim vaskulitisima obiÄno je meotreksat ili azatioprin. Od bioloÅ”kih lijekova dosta se oÄekuje od primjene tocilizumaba u giganatocelularnom arteritisu, dok je u s ANCA povezanim vaskulitisma nedavno od regualatornih tijela odobrena primjena rituksimaba koji se smatra jednakovrijedan ciklofosfamidu u indukciji remisije, a preferira se u relapsnim oblicima bolesti.Treatment of vasculitis depends on etiology and type of vasculitis. Gluccocorticoids are drug of choice in treatment of systemic vasculitis. While in vasculitis of large vessels treatment with gluccocorticoids is often sufficient, in ANCA associated vasculitis almost always intial combination of gluccocorticoids and immunosupresive drugs (cyclofosfamide in severe forms; azatioprin and metotrrexate in moderate disease) is needed. Maintance therapy of ANCA associated vasculitis is methotrexate or azatioprin. From biologic therapy, in gigantocellular vasculitis treatment with tocilizumb has a great expectation, while in ANCA associated vasculitis recently rituximab was approved by regulatory agencies, and it is nontinferior to cyclofosfamide in induction of remission and prefarable in relapsing disease
Treatment of vasculitis
LijeÄenje vakulitisa ovisi o etiologiji i tipu vaskulitisa. U lijeÄenju sistemskih vaskulitisa glukokortikodi su prvi lijekovi izbora. Dok je u vaskulitisima velikih krvnih žila Äesto dovoljna primjena samo glukokortikoida u s ANCA povezanim vaskulitisima gotovo uvijek je potrebna inicijalna kombinacija glukokortikoida i imunosupresiva (u težim oblicima ciklofosfamid, a u lakÅ”im metotreksat ili azatioprin). Terapija održavanja u s ANCA povezanim vaskulitisima obiÄno je meotreksat ili azatioprin. Od bioloÅ”kih lijekova dosta se oÄekuje od primjene tocilizumaba u giganatocelularnom arteritisu, dok je u s ANCA povezanim vaskulitisma nedavno od regualatornih tijela odobrena primjena rituksimaba koji se smatra jednakovrijedan ciklofosfamidu u indukciji remisije, a preferira se u relapsnim oblicima bolesti.Treatment of vasculitis depends on etiology and type of vasculitis. Gluccocorticoids are drug of choice in treatment of systemic vasculitis. While in vasculitis of large vessels treatment with gluccocorticoids is often sufficient, in ANCA associated vasculitis almost always intial combination of gluccocorticoids and immunosupresive drugs (cyclofosfamide in severe forms; azatioprin and metotrrexate in moderate disease) is needed. Maintance therapy of ANCA associated vasculitis is methotrexate or azatioprin. From biologic therapy, in gigantocellular vasculitis treatment with tocilizumb has a great expectation, while in ANCA associated vasculitis recently rituximab was approved by regulatory agencies, and it is nontinferior to cyclofosfamide in induction of remission and prefarable in relapsing disease
The efficacy and safety of the combination of leflunomide (AravaĀ®) and biological agents in treatment of rheumatoid arthritis
U radu je prikazana uÄinkovitost i sigurnost primjene kombinacije leflunomida (AravaĀ®) i bioloÅ”kih lijekova u lijeÄenju reumatoidnog artritisa.The efficacy and safety of the combination of leflunomide (AravaĀ®) with biological agents in treatment of rheumatoid arthritis is are presented
Nove EULAR-ove preporuke za lijeÄenje reumatoidnog artritisa sintetskim i bioloÅ”kim antireumatskim lijekovima koji mijenjaju tijek bolesti
Antiresorptive agents in the treatment of osteoporosis
Cilj medikamentoznog lijeÄenja osteoporoze jest uspostaviti ravnotežu izmeÄu aktivnosti osteoblasta i osteoklasta te time poveÄati mineralnu gustoÄu kosti i posljediÄno smanjiti rizik prijeloma. Antiresorptivni lijekovi suprimiraju djelovanje osteoklasta te na taj naÄin smanjuju razgradnju kosti. Tu pripadaju bisfosfonati, selektivni modulatori estrogenskih receptora (SERM) te denosumab, dok su hormonsko nadomjesno lijeÄenje i kalcitonin danas uglavnom napuÅ”teni. VežuÄi se za kristale hidroksiapatita na povrÅ”ini kosti bisfosfonati inhibiraju resorpciju kosti te posljediÄno dovode do smanjenja rizika za vertebralne i nevertebralne prijelome. Denosumab je monoklonsko protutijelo koje spreÄavanjem interakcije izmeÄu RANKL-a i RANK-a inhibira osteoklastogenezu i tako smanjuje resorpciju kosti u kortikalnoj i trabekularnoj kosti te posljediÄno znatno smanjuje rizik za prijelome.The aim of drug treatment of osteoporosis is the balance between activity of osteoblasts and osteoclasts with augmentation of mineral bone density and decrease of fracture risk. Antiresorptive agents depress osteoclasts and diminish resorption of bone. They include bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab, while hormone replacement therapy and calcitonin are mostly abandoned. By binding to hydroxyapatite crystals of bone surface bisphosphonates inhibit the resorption of bone and prevent vertebral and non-vertebral fractures. Denosumab is a monoclonal antibody which by hindering interaction between RANKL and RANK inhibits osteoclastogenesis and diminishes bone resorption in cortical and trabecular bones, thus significantly lessening fracture risk
Nove EULAR-ove preporuke za lijeÄenje reumatoidnog artritisa sintetskim i bioloÅ”kim antireumatskim lijekovima koji mijenjaju tijek bolesti
Strontium ranelate (OsseorĀ®) - unique double mechanism - physiologic bone treatment as live tissue
Interstitial lung disease (ILD) in systemic sclerosis (SSc)
Intersticijska bolest pluÄa je Äesta komplikacija sistemske skleroze koja nerijetko ima loÅ”u prognozu te je zajedno s pluÄnom arterijskom hipertenzijom najÄeÅ”Äi uzrok smrti u ovoj bolesti. U otkrivanju i praÄenju iste, najvažnije metode su CT visoke rezolucije te funkcionalni testovi pluÄne funkcije. Odluka o zapoÄinjanju lijeÄenja Äesto je vrlo teÅ”ka. Kandidati za imunosupresivno lijeÄenje su obiÄno bolesnici u kojih sistemska bolest kratko traje i u kojih dolazi do naglog pada DCO. Kao lijek izbora najÄÅ”Äe se spominje cikolofosfamid primjenjen intavavenski u mjeseÄnim intervalima zajedno s malim dozama glukokortikoida iako se u lijeÄenju primjenjuju i drugi imunosupresivi, najÄeÅ”Äe azatioprin ili mikofenolat mofetil.Intersitial lung disease is a frequent complication of systemic sclerosis that often has a poor pognosis and together with pulmonary arterial hypertension are the most common cause of death in scleroderma patients. For detection and evaluation of interstitial lung disease, high-resolution CT and pulmorary functional tests are pivotal. The decision about whether to start treatment is often the most difficult challenge. Patients with short duration of systemic disease with recent deterioration in DCO are the candidates for immunosupressive therapy. Best current initial treatment is intravenous monthly cyclophosphamide together with low-dose oral glucocorticoids although azathioprine and mycophenolate mofetil are also widelly used
- ā¦